-
The Future Of Nano Technology
Categories
- Ai
- Alan Watts
- Anatomy
- Andropause
- Anti-Aging Medicine
- Arthritis
- Artificial General Intelligence
- Artificial Intelligence
- Artificial Super Intelligence
- Ataxia
- Autism
- Biochemistry
- BioEngineering
- Biotechnology
- Bitcoin
- Chemistry
- Cryonics
- Cryptocurrency
- David Sinclair
- Dementia
- Diet Science
- Diseases
- Eczema
- Elon Musk
- Futurism
- Gene Medicine
- Gene Therapy
- Gene therapy
- Genetic Medicine
- Genetic Therapy
- Global News Feed
- Healthy Lifestyle
- Healthy Living
- HGH Physicians
- Hormone Optimization
- Hormone Replacement Therapy
- Hormone Replacement Treatment
- Human Genetic Engineering
- Human Immortality
- Human Longevity
- Human Reproduction
- Hypogonadism
- Hypopituitarism
- Hypothyroidism
- Immortality
- Immortality Medicine
- Inflammation
- Injectable Growth Hormone
- Integrative Medicine
- Life Skills
- Longevity
- Longevity Medicine
- Low T
- Machine Learning
- Mars Colony
- Medical School
- Menopause
- multiple-sclerosis
- Nano Medicine
- Nanomedicine
- Nanotechnology
- Neurology
- Parkinson's disease
- Pharmacogenomics
- Protein Folding
- Psoriasis
- Quantum Computing
- Regenerative Medicine
- Resveratrol
- Sermorelin Physicians
- Singularity
- Spacex
- Stem Cell Therapy
- Stem Cells
- Stemcell Therapy
- Testosterone
- Testosterone Physicians
- Transhuman
- Transhumanism
- Transhumanist
- Uncategorized
- Veganism
- Vegetarianism
- Vitamin Research
- Wellness
-
Recent Posts
- Polyplus Launches Innovative Plasmid for AAV Vector Production, Strengthening Its Position in Biologic and Cell … – BSA bureau
- Orchard Sets $4.25M US Price for Gene Therapy Lenmeldy on Heels of Approval – BioSpace
- Stem Cell Editing Repairs Severe Immunodeficiency – The Scientist
- Opus Genetics Announces Completion of Dosing in First Cohort of Phase 1/2 Trial of Gene Therapy OPGx-LCA5 in … – GlobeNewswire
- New Gene Therapy for Rare MDL to Cost $4.25 Million – Managed Healthcare Executive
Archives
Popular
Search Immortality Topics: |
Category Archives: Global News Feed
Scilex Holding Company Generates Monthly Revenue In November 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales…
PALO ALTO, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced monthly revenue in November 2023 and provided certain preliminary unaudited financial results for gross and net sales for the one month ended November 2023 and year-to-date through November 30, 2023.
Go here to read the rest:
Scilex Holding Company Generates Monthly Revenue In November 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales...
Posted in Global News Feed
Comments Off on Scilex Holding Company Generates Monthly Revenue In November 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales…
Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting
MIAMI, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Amy Chappell, M.D., FAAN, will be presenting preclinical in vivo data evaluating BAER-101 using the SynapCell's Genetic Absence Epilepsy Rat from Strasbourg (“GAERS”) model of absence epilepsy at the American Epilepsy Society (AES) 2023 Annual Meeting in Orlando, FL on December 2, 2023.
Read the original here:
Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting
Posted in Global News Feed
Comments Off on Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting
Neurona Therapeutics Presents New Clinical Data from First Cohort in Ongoing Phase I/II Open-Label Trial of NRTX-1001 Cell Therapy for Drug-resistant…
NRTX-1001 investigational treatment has been well tolerated in all initial subjects
Read this article:
Neurona Therapeutics Presents New Clinical Data from First Cohort in Ongoing Phase I/II Open-Label Trial of NRTX-1001 Cell Therapy for Drug-resistant...
Posted in Global News Feed
Comments Off on Neurona Therapeutics Presents New Clinical Data from First Cohort in Ongoing Phase I/II Open-Label Trial of NRTX-1001 Cell Therapy for Drug-resistant…
RetinalGeniX Technologies Inc. Announces Hiring of Interim CFO
Virender Ahluwalia will serve as Interim Chief Financial Officer Virender Ahluwalia will serve as Interim Chief Financial Officer
Continued here:
RetinalGeniX Technologies Inc. Announces Hiring of Interim CFO
Posted in Global News Feed
Comments Off on RetinalGeniX Technologies Inc. Announces Hiring of Interim CFO
Number of voting rights as of November 30, 2023
Nicox SA Société anonyme with a registered capital of € 50,170,498
Posted in Global News Feed
Comments Off on Number of voting rights as of November 30, 2023
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC
Regulated Information
Read more from the original source:
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC
Posted in Global News Feed
Comments Off on Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC